Hikma Stays On Track By Bolstering Injectables And Generics

Benefits From Xellia And Contract Manufacturing Deals

 
• By Dave Wallace
  
Hikma says it is on target to meet its full-year forecasts (Shutterstock)

More from Earnings

More from Generics Bulletin